Scarica l'app Stockscreener
18.07
1.18%
0.21
Dopo l'orario di chiusura:
17.90
-0.17
-0.94%
Rapport Therapeutics Inc Borsa (RAPP) Ultime notizie
When (RAPP) Moves Investors should Listen - Stock Traders Daily
1,684 Shares in Rapport Therapeutics (NASDAQ:RAPP) Bought by BNP Paribas Financial Markets - Defense World
Rapport Therapeutics (NASDAQ:RAPP) Shares Down 4.6%Should You Sell? - MarketBeat
Rapport Therapeutics (NASDAQ:RAPP) Stock Price Up 5.7%Should You Buy? - MarketBeat
Charles Schwab Investment Management Inc. Buys New Stake in Rapport Therapeutics (NASDAQ:RAPP) - Defense World
Charles Schwab Investment Management Inc. Takes Position in Rapport Therapeutics (NASDAQ:RAPP) - MarketBeat
CAMP4 Appoints John Maraganore and Rachel Meyers as Strategic Advisors - The Manila Times
(RAPP) Proactive Strategies - Stock Traders Daily
Companies Like Rapport Therapeutics (NASDAQ:RAPP) Can Afford To Invest In Growth - Simply Wall St
We're Not Worried About Rapport Therapeutics' (NASDAQ:RAPP) Cash Burn - Yahoo Finance
Rapport Therapeutics Presents Data Demonstrating Consistent - GlobeNewswire
Rapport Therapeutics Breakthrough: New Epilepsy Treatment Biomarker Shows Strong Clinical Seizure Correlation | RAPP Stock News - StockTitan
Maven Securities LTD Takes Position in Rapport Therapeutics (NASDAQ:RAPP) - MarketBeat
Fmr LLC Raises Stock Position in Rapport Therapeutics (NASDAQ:RAPP) - MarketBeat
Rapport Therapeutics' Lock-Up Period To Expire on December 4th (NASDAQ:RAPP) - MarketBeat
Rapport Therapeutics’ Lock-Up Period Will Expire on December 4th (NASDAQ:RAPP) - Defense World
Two new option listings and one option delisting on November 21st - TipRanks
Rapport Therapeutics Reports Q3 Financials and Strategic Updates - MSN
LMR Partners LLP Sells 30,000 Shares of Rapport Therapeutics (NASDAQ:RAPP) - MarketBeat
(RAPP) Investment Analysis and Advice - Stock Traders Daily
Rapport Therapeutics (NASDAQ:RAPP) Trading Down 6.5% – Should You Sell? - Defense World
Rapport Therapeutics (NASDAQ:RAPP) Shares Down 6.5%Time to Sell? - MarketBeat
Cormorant Asset Management's Strategic Acquisition in Rapport Th - GuruFocus.com
Rapport Therapeutics to Present Data at American Epilepsy Society Annual Meeting - GlobeNewswire
Rapport Therapeutics to Present Phase 2a Epilepsy Drug Data at Major Conference | RAPP Stock News - StockTitan
FMR LLC's Strategic Acquisition in Rapport Therapeutics Inc - GuruFocus.com
Q3 Biotech Earnings Recap: Nkarta, Intellia, Cassava and more - BioSpace
Cartesian Therapeutics (NASDAQ:RNAC) & Rapport Therapeutics (NASDAQ:RAPP) Head to Head Comparison - Defense World
CRISPR Therapeutics AG (CRSP) Reports Q3 Loss, Lags Revenue Estimates - MSN
(RAPP) Investment Report - Stock Traders Daily
Rapport Therapeutics Inc (RAPP) Quarterly 10-Q Report - Quartzy
Rapport Therapeutics Reports Third Quarter Financials and Provides Business Update - The Manila Times
Rapport (RAPP) Hit With FDA Hold Despite $320M Cash Position; Q3 Loss Widens | RAPP Stock News - StockTitan
Rapport Therapeutics to Present at Stifel Healthcare - GlobeNewswire
Rapport Therapeutics to Present at Stifel Healthcare Conference and Jefferies London Healthcare Conference in November - StockTitan
Rapport Therapeutics (NASDAQ:RAPP) Shares Gap Up – Still a Buy? - Defense World
Rapport Therapeutics (NASDAQ:RAPP) Shares Gap UpHere's Why - MarketBeat
SG Americas Securities LLC Makes New Investment in Rapport Therapeutics (NASDAQ:RAPP) - Defense World
(RAPP) Trading Report - Stock Traders Daily
Rapport Therapeutics (NASDAQ:RAPP) Trading Down 4.2%Here's Why - MarketBeat
Rapport Therapeutics (NASDAQ:RAPP) Shares Gap DownShould You Sell? - MarketBeat
Jones Trading Initiates Coverage of Rapport Therapeutics (RAPP) with Buy Recommendation - MSN
Rapport Therapeutics (NASDAQ:RAPP) Trading Down 2.7%Time to Sell? - MarketBeat
This Rapport Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - MSN
Rapport Therapeutics (NASDAQ:RAPP) Sets New 1-Year HighTime to Buy? - MarketBeat
Millennium Management LLC Makes New $2.72 Million Investment in Rapport Therapeutics (NASDAQ:RAPP) - MarketBeat
Rapport Therapeutics (NASDAQ:RAPP) Short Interest Up 32.4% in September - MarketBeat
Rapport Therapeutics (NASDAQ:RAPP) Stock Price Up 5.3%What's Next? - MarketBeat
75,516 Shares in Rapport Therapeutics (NASDAQ:RAPP) Purchased by The Manufacturers Life Insurance Company - MarketBeat
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):